TITLE:
A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.

CONDITION:
Colorectal Cancer

INTERVENTION:
ALIMTA

SUMMARY:

      The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin
      combination therapy in patients with previously untreated advanced colorectal cancer
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Diagnosis of primary cancer of the colon or rectum

          -  Must have measurable disease

          -  Must be able to comply with study procedure

        Exclusion Criteria:

          -  Prior chemotherapy for advanced disease

          -  Pregnancy or lactation

          -  Candidates for surgical resection of one or more metastatic foci

          -  Second primary cancer

          -  Inability to take folic acid or vitamin B12
      
